University Of Pittsburgh Researchers Detect High Levels Of HIV In Semen At All Stages Of Disease

January 25, 1997

NOTE TO EDITORS: University of Pittsburgh researchers announced today that the amount of freely circulating virus, or viral load, in semen of HIV-infected men at all stages of disease is up to 1,000 times greater than previously measured. Viral load is quantified by measuring the genetic material of the virus, HIV-1 RNA. In this report, researchers suggest that semen viral load provides the best indication for the rate of sexual transmission. Researchers also propose that to prevent the spread of AIDS, vaccines should be developed against viral strains that develop in semen but not in blood.

WASHINGTON, D.C., Jan. 22 -- Researchers have focused extensively on controlling HIV-1 RNA levels in the blood of HIV-infected individuals to treat AIDS. But to stem the major route of transmission and overall spread of AIDS, they must look at the activity of HIV in the semen. Researchers from the University of Pittsburgh have detected free HIV-1 RNA, or viral load, at levels 10 to 1000 times greater in all stages of disease than previously measured in the semen of HIV-infected men.

"This study substantiates concern that a man can transmit HIV at any time after his initial infection," cautioned Phalguni Gupta, Ph.D., associate professor of infectious diseases and microbiology at the University of Pittsburgh Graduate School of Public Health, who will present these findings at 10:30 a.m. (EST) on Saturday, Jan. 25, at the Fourth Annual Conference on Retroviruses and Opportunistic Infections in Washington, D.C.

Using the NASBA (Nucleic Acid Sequence Based Amplification, Organon Teknika) method, researchers quantified the HIV-1 RNA in semen and blood samples from 34 homosexual men at varying stages of the disease. They found that viral load in both blood and semen accurately monitors viral activity. In this first report to monitor semen viral load over an extended period of time, researchers found that semen viral load increases with progression of the disease in the majority of patients.

"We believe that a unique strain of virus could have arisen in the semen but not in the blood," Dr. Gupta commented. Attributing the evolution of the virus in the semen to biological differences in the seminal and blood environments, Dr. Gupta said that "to prevent transmission of the virus through the primary mode of transmission -- sexual contact -- we need to devise a vaccine against the strain of virus that is present in the semen."

This study also is the first to show that using antiviral therapy reduces viral load in semen. Administering a combination therapy consisting of a nonnucleoside reverse transcriptase inhibitor and a protease inhibitor diminishes the viral load below detectable levels in both semen and blood in a total of six patients examined. Nonnucleoside reverse transcriptase inhibitors interfere with the replication of the virus, while protease inhibitors block the process of packaging viral genetic messages.

"We have determined in previous studies that reduction of viral load in blood plasma improves patient prognosis," said John W. Mellors, M.D., associate professor of medicine at the University of Pittsburgh Medical Center (UPMC). "It has been difficult to quantify viral activity in other organs and tissues, which has prohibited an accurate portrayal of overall viral load in the body and the response to therapy." Accurate detection of viral load in the semen, "offers researchers one more tool to analyze disease activity in other tissues and helps to gauge the effectiveness of new therapies," according to Dr. Mellors.

Other Pitt investigators involved in the study are: Charles Rinaldo, Ph.D., professor of pathology and microbiology and director of the Pitt Men's Study; Lawrence A. Kingsley, Dr.P.H., associate professor of epidemiology and microbiology; Sharon Riddler, M.D., assistant professor; and Mandaleshwar Singh, Ph.D., research assistant professor. Researchers from Organon Teknika include Susanna Schreiber, Ph.D., and Michael Cronin, M.S.

The Pitt Men's Study is one of four centers participating in the National Institute of Allergy and Infectious Diseases Multi-center AIDS Cohort Study, a long-term research project focused on HIV-infected men.

HIV/AIDS researchers at the UPMC have pioneered the use of viral load testing in HIV-infected patients, triple-drug therapy to reduce disease activity and topical agents to prevent sexual transmission of HIV in women. UPMC investigators also are conducting research on AIDS-related malignancies and dementia, AIDS vaccines and AIDS prevention strategies.

# # #

University of Pittsburgh Medical Center

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.